Therefore, I-FABP may be more suitable as a marker for assessing obvious damage to the intestinal barrier, such as gastrointestinal cancer, intestinal obstruction, necrotizing colitis, etc., and may not be applicable in the early stages of certain diseases, such as NAFLD-associated intestinal barrier functions. Here, FABP2 is linked to metabolic dysfunction-associated steatotic liver disease.